Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting
- Data Provide Insights in Preparation for Investigational New Drug (IND) Submissions Planned in 2019 for ALLO-501 (anti-CD19) in Non-Hodgkin Lymphoma and ALLO-715 (anti-BCMA) in Multiple Myeloma
“ASH is the first significant medical meeting where we will present data
on programs led by Allogene,” said
The ASH abstracts are now available at www.hematology.org. The oral and poster presentations will include additional data not available in the abstracts. Details are as follows.
Allogene Oral Presentation
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies,
excluding Therapy: Development of Novel Immunotherapeutic Approaches in
Multiple Myeloma
Abstract #591
Title: ALLO-715,
an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the
Treatment of Multiple Myeloma
Presenter:
Session Date & Time:
Presentation Time:
Location: Ballroom 20D
Allogene Poster Presentation
Session: 703. Adoptive Immunotherapy: Poster II
Abstract #3335
Title:
ALLO-819, an Allogeneic Flt3 CAR T Therapy Possessing an Off-Switch
for the Treatment of Acute Myeloid Leukemia
Presenter:
Session Date & Time:
Location: Hall GH
Oral Presentation in Collaboration with Development Partner
UCART19,
sponsored by Servier1, is in Phase 1 development for the
treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Session: 612. Acute Lymphoblastic Leukemia: Clinical
Abstract
#896
Title: Preliminary Data on Safety, Cellular
Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19
CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with
High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Presenter:
Session Date & Time:
Presentation time:
Location:
Room 6A
UCART19, ALLO-715 and ALLO-819 utilize the TALEN® gene-editing
technology pioneered and owned by
UCART19, initially developed by
ALLO-715 and ALLO-819 were progressed under a joint research
collaboration with
About
AlloCAR T™ cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an AlloCAR T™ therapy candidate currently in Phase 1 sponsored by Servier for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the progress and
success of the allogeneic CAR T clinical program and the timing of
filing Investigational New Drug applications relating to ALLO-501 and
ALLO-715. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the
1 Servier is an independent international pharmaceutical
company, governed by a foundation, with Headquarters based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005635/en/
Source:
Allogene Media/Investor Contact:
Christine Cassiano,
714-552-0326
Chief Communications Officer
Christine.Cassiano@allogene.com